Presidio snags preclinical hep C program for $108M

XTL Biopharmaceuticals is pocketing a $4 million upfront fee and stands to earn another $104 million in milestones after inking a collaboration deal with Presidio Pharmaceuticals for its preclinical hepatitis C program. NS5A is in advanced stages of lead optimization. As part of the license, Presidio obtained rights to several distinct chemical series, including their lead series, which exhibits activity against both the HCV 1a and 1b genotypes. Presidio will assume responsibility for any additional lead optimization, clinical development, and commercialization activities related to the program.

"This license agreement with XTL expands the HCV franchise we created in our ongoing agreements with Stanford and Numerate, and firmly establishes Presidio as a leading developer of medicines for HCV," said Omar K. Haffar, Presidio's president and CEO.

- read the release
- check out the AFX report

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.